Publications
Publications
Show Results For
- All HBS Web
(3,284)
- Faculty Publications (1,403)
- March 2024
- Supplement
Negotiating the Gift of Life (B)
By: Alex Chan
Describes a negotiation where lives are truly at stake, where key lessons on persuasion and the role that identity might play in a negotiation are on display through an effort by a frontline negotiator from OneLegacy, the US's largest organ procurement organization. As... View Details
- March 2024 (Revised July 2024)
- Case
WeightWatchers: Promoting Weight Health
In December 2023, the 60-year-old weight management industry stalwart WeightWatchers announced the launch of WeightWatchers Clinic, which incorporated GLP-1s , a new class of prescription weight-loss medications, into the company’s portfolio of products and mobile app... View Details
- March 2024 (Revised July 2024)
- Case
AMC: The Zero Revenue Case
By: C. Fritz Foley and Donal O'Cofaigh
The onset of the Covid-19 pandemic put theatre company AMC’s already perilous financial situation under even further strain. The company’s high levels of debt resulted in a monthly cash-burn which left it facing an imminent Chapter-11 filing in the absence of... View Details
- March 2024
- Article
Investigation of Divergent Thinking among Surgeons and Surgeon Trainees in Canada (IDEAS): A Mixed-methods Study
By: Alex Thabane, Tyler McKechnie, Vikram Arora, Goran Calic, Jason W Busse, Ranil Sonnadara and Mohit Bhandari
Objective: To assess the creative potential of surgeons and surgeon trainees, as measured by divergent thinking. The secondary objectives were to identify factors associated with divergent thinking, assess confidence in creative problem-solving and the perceived effect... View Details
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
- February 2024
- Teaching Note
AB InBev: Brewing Up Forecasts during COVID-19
By: Mark Egan and C. Fritz Foley
Teaching Note for HBS Case No. 224-020. In July 2021, the CEO of AB InBev's European operations and his team strategized to position the company for success post-pandemic. As the world's largest beer company, boasting over 500 brands, revenue of $46 billion, and a... View Details
- February 2024
- Case
Oak Street Health: From Start-up to Strategic Acquisition
By: Leemore S. Dafny and Thomas H. Lee
Oak Street Health opened its first primary care center for seniors in underserved communities in 2013. By 2022 the company had 169 centers and a market valuation exceeding $10 billion. Oak Street created value by accepting risk-adjusted, capitated payments for Medicare... View Details
- February 2024 (Revised December 2024)
- Case
Best Buy Health: Enabling Care at Home
This case explores retailer Best Buy’s decision to enter health care. Best Buy Health aims to enable care at home across three prongs: consumer health, active aging, and virtual care. A key pillar of Best Buy Health's strategy is leveraging the Geek Squad—the company's... View Details
- February 2024
- Article
An Economic Framework for Vaccine Prioritization
By: Mohammad Akbarpour, Eric Budish, Piotr Dworczak and Scott Duke Kominers
We propose an economic framework for determining the optimal allocation of a scarce supply of vaccines that become gradually available during a public health crisis, such as the Covid-19 pandemic. Agents differ in observable and unobservable characteristics, and the... View Details
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
- February 2024
- Teaching Note
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul
Teaching Note for HBS Case No. 724-412. View Details
- February 2024
- Article
Representation and Extrapolation: Evidence from Clinical Trials
By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams
This article examines the consequences and causes of low enrollment of Black patients in clinical
trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is
more relevant for decision-making by physicians and patients when it... View Details
- January 2024
- Supplement
Buurtzorg
By: Ethan Bernstein and Tatiana Sandino
As co-founders of home nursing company Buurtzorg, Jos de Blok and Gonnie Kronenberg prized both self-management and organizational learning. Buurtzorg’s 10,000 nurses across 950 neighborhood nursing teams in the Netherlands were empowered to manage themselves, both in... View Details
- January 2024 (Revised October 2024)
- Case
DO & CO: Crafting Luxury in the Fast Lane (A)
By: Juan Alcácer, Esel Cekin, Michael Lee and Noah Roberson
In July 2023, Attila Dogudan, the chairman of DO & CO, a renowned international catering firm, found himself in a deep conversation with his two sons about a potential new venture: catering for the Las Vegas Grand Prix, a significant step beyond their 31-year history... View Details
- January 2024 (Revised April 2024)
- Teaching Note
Somatus: Value-Based Kidney Care (A) & (B)
By: Ariel D. Stern, Robert S. Huckman and Sarah Mehta
This teaching note accompanies case no. 622-009 and 622-045 (Somatus: Value-Based Kidney Care, A and B). View Details
- January 2024
- Background Note
Evaluating Innovations in the Organization of Primary Care: What Type of Innovation Is It and How Well Does It Align with the Six Factors?
By: Regina E. Herzlinger and James Wallace
How can we evaluate if innovative health care ventures can do good—benefit society—and do well—become financially viable? This question is the topic of the first module in the Innovating in Health Care course book.
This note and "Health Stop (A): What Type... View Details
This note and "Health Stop (A): What Type... View Details
- January 2024
- Case
Vibrant Health
By: Henry McGee and Sarah Mehta
This case is about nutritional supplements company Vibrant Health, among the 100 largest Black-owned businesses in the U.S. After acquiring the company from its white founder in 2007, co-owners Ted and Paige Parker significantly grew its sales. Set in September 2023,... View Details
- January 2024
- Article
A Cost Model for a Low Threshold Clinic Treating Opioid Use Disorder
By: Sarah E. Wakeman, Elizabeth Powell, Syed Shehab, Grace Herman, Laura Kehoe and Robert S. Kaplan
The US fee-for-service payment system under-reimburses clinics offering access to comprehensive treatments for opioid use disorder (OUD). The funding shortfall limits a clinic’s ability to expand and improve access, especially for socially marginalized patients with... View Details
- January 2024
- Article
Cost of Exempting Sole Orphan Drugs from Medicare Negotiation
By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details
Objective: To estimate Medicare spending and global... View Details
- December 2023 (Revised March 2024)
- Case
Manufacturing Moderna's Future
By: Satish Tadikonda and William Marks
In 2019, Moderna faced long odds of survival having failed to develop a successful clinical program out of the vast platform technology they had built around mRNA. Nearly overnight, the company skyrocketed to success with a vaccine for COVID-19, leading to an extremely... View Details